20
Participants
Start Date
December 12, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
SBRT + MEDI5752
"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"
Institut Bergonié, Bordeaux
Centre Oscar Lambret, Lille
Centre Leon Berard, Lyon
Institut Regional Du Cancer de Montpellier, Montpellier
IUCT-O, Toulouse
Collaborators (1)
National Cancer Institute, France
OTHER_GOV
AstraZeneca
INDUSTRY
Institut Claudius Regaud
OTHER